Page last updated: 2024-11-05

thalidomide and Chronic Bullous Disease of Childhood

thalidomide has been researched along with Chronic Bullous Disease of Childhood in 2 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Maione, V3
Bettolini, L3
Venturuzzo, A3
Tonon, F3
Battocchio, S3
Calzavara-Pinton, P3
Lu, Z1
Su, D1
Li, X1
Da, Z1

Other Studies

2 other studies available for thalidomide and Chronic Bullous Disease of Childhood

ArticleYear
Efficacy of apremilast in a case of resistant linear IgA bullous disease.
    International journal of dermatology, 2023, Volume: 62, Issue:5

    Topics: Humans; Immunoglobulin A; Linear IgA Bullous Dermatosis; Skin Diseases, Vesiculobullous; Thalidomide

2023
Efficacy of apremilast in a case of resistant linear IgA bullous disease.
    International journal of dermatology, 2023, Volume: 62, Issue:5

    Topics: Humans; Immunoglobulin A; Linear IgA Bullous Dermatosis; Skin Diseases, Vesiculobullous; Thalidomide

2023
Efficacy of apremilast in a case of resistant linear IgA bullous disease.
    International journal of dermatology, 2023, Volume: 62, Issue:5

    Topics: Humans; Immunoglobulin A; Linear IgA Bullous Dermatosis; Skin Diseases, Vesiculobullous; Thalidomide

2023
Efficacy of apremilast in a case of resistant linear IgA bullous disease.
    International journal of dermatology, 2023, Volume: 62, Issue:5

    Topics: Humans; Immunoglobulin A; Linear IgA Bullous Dermatosis; Skin Diseases, Vesiculobullous; Thalidomide

2023
LABD-like manifestation in a patient with systemic lupus erythematosus.
    Rheumatology (Oxford, England), 2021, 06-18, Volume: 60, Issue:6

    Topics: Cyclophosphamide; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Linear IgA Bullous Derm

2021